On February 6, 2023 RNAimmune, Inc. (the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, reported that its RNAimmune mRNA cancer vaccine program has been accepted for oral presentation at the AACR (Free AACR Whitepaper) Annual Meeting 2023 (Press release, RNAimmune, FEB 6, 2023, View Source [SID1234626897]). The AACR (Free AACR Whitepaper) Annual Meeting will take place April 14-19 in Orlando, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: A pan-ras mRNA vaccine elicits specific immune responses and inhibits tumor growth in the mouse model of colon cancer

Presenter: Dong Shen, MD PhD, RNAimmune founder and President

Session Category: Experimental and Molecular Therapeutics

Session Title: New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling

Session Date/Time: Tuesday, Apr 18, 2023, 2:30 PM – 4:30 PM ET

Note: The presentation will also be published in the online Proceedings of the AACR (Free AACR Whitepaper).

Venue: Orange County Convention Center, Orlando, Florida

RNAimmune will present a pre-clinical study showing the most recent mRNA cancer vaccine progress. The study shows immunization of the mRNA vaccine can elicit T and B cell responses, which are crucial in anti-cancer immunotherapy, and inhibit tumor growth in the mouse model of colon cancer, prolonging survival. Notably, the anti-tumor effect is further enhanced in the combination of anti-PD1 antibody.

RAS is one of the most common mutated oncogenes in human cancer. Unfortunately, there is still a lack of specifically effective medication for most RAS-mutated cancer patients. For G12C-mutated patients, drug resistance frequently appears soon after targeted therapy. The reported Pan RAS mRNA cancer vaccine was designed and screened by RNAimmune, which owns its proprietary independent intellectual property rights. Its anti-tumor effects have been validated both in vitro and in vivo. The current program yielded outstanding antitumor activity, and the Company plans to submit to the U.S. Food and Drug Administration an Investigational New Drug application after completion of the current dose titration study.

Found in 1907, AACR (Free AACR Whitepaper) is the first and largest cancer research organization dedicated to fighting against cancer. The annual meeting of AACR (Free AACR Whitepaper) is one of the biggest meetings in the global cancer research community, and it highlights the latest advances in anti-cancer research and development from all over the world.

On February 6, 2023 Aethlon Medical, Inc. (NASDAQ: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, reported that it will issue financial results for its third quarter ended December 31, 2022, at 4:15 p.m. EST on Monday, February 13, 2023 (Press release, Aethlon Medical, FEB 6, 2023, https://www.prnewswire.com/news-releases/aethlon-medical-to-release-third-quarter-financial-results-and-host-conference-call-on-february-13-2023-301738635.html [SID1234626896]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will host a conference call on Monday, February 13, 2023 at 4:30 p.m. EST to review financial results and recent corporate developments. Following management’s formal remarks, there will be a question and answer session.

Interested parties can register for the conference by navigating to View Source Please note that registered participants will receive their dial in number upon registration.

Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.

A replay of the call will be available approximately one hour after the end of the call through March 13, 2023. The replay can be accessed via Aethlon Medical’s website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 4716809.

On February 6, 2023 J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibitor (TKI) targeting HER2 Exon20 insertion mutation in NSCLC, will be presented at the upcoming 2023 American Cancer Research Association meeting in Orlando, U.S. from April 14 to 19 (Press release, J INTS BIO, FEB 6, 2023, View Source [SID1234626895]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HER2 Exon20 insertion mutation accounts for 2-3% of NSCLC and there is currently no approved oral targeted therapy.

"JIN-A04" showed potent efficacy against HER2 Exon20 insertion mutant NSCLC cell lines, and in-vivo mouse models using HER2 Exon20 insertion mutant cell lines significant tumor regression was demonstrated.

J INTS BIO completed the application for designation of ‘JIN-A04’ as an orphan drug with the US FDA in August last year and said that the procedure for designation as an orphan drug is in progress. As a result, the company said, "If JIN-A04 is approved for designation as an orphan drug, it will be possible for it to be used in patients after the completion of Phase 1 and Phase 2 clinical trials." To this end, the company plans to submit an IND to the US and Korea in the first half of this year, allowing us to enter Phase 1 clinical study in the US and Korea simultaneously.

On February 6, 2023 Presage Biosciences, a biotechnology company whose mission is understanding the complexity of drug response in the tumor microenvironment, reported that it has entered into a new research collaboration with Poland-based biopharmaceutical company Pure Biologics to evaluate two of Pure Biologics’ very early stage assets in a Phase 0 intratumoral microdosing study (Press release, Presage Biosciences, FEB 6, 2023, View Source [SID1234626894]). Presage’s CIVO platform will be used to evaluate drug mechanism of action, potential indicators of efficacy, and drug combinations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to work with a forward-thinking partner who grasps the power of Phase 0 for cancer drug development and the insights we can gain from drug-exposed areas of the human tumor microenvironment," said Rich Klinghoffer, PhD, Presage CEO. "We see this partnership as a tremendous opportunity for Presage to continue innovating and delivering key pharmacodynamic insights into a partner’s early-stage oncology assets."

"The tumor microenvironment is complex and we are enthusiastic about Presage’s innovative approach to obtain information about the effectiveness of our compounds faster than traditional Phase I and Phase II trials," said Dr. Filip Jelen, Pure Biologics Co-Founder and President of the Management Board. "Their CIVO platform will allow us to introduce our novel agents directly into patient tumors and provide the first real clues about drug efficacy."

The collaboration with Pure Biologics comes on the heels of Presage’s recently completed Phase 0 clinical trials (NCT04065555 and NCT04541108) with Takeda Pharmaceutical Company evaluating immune-oncology drugs alone and in combination in head and neck cancer patients. The trials demonstrated that CIVO is able to deliver key spatial biology and mechanistic insights. Presage expects to publish the results from both studies later this year.

About CIVO
Comparative In Vivo Oncology (CIVO) is Presage’s patented platform that enables multiplexed intratumoral microdosing and generation of detailed tumor profiling. Presage’s CIVO technology and analysis capabilities are unparalleled at providing insight into drug-exposed areas of the intact tumor microenvironment. Presage is pairing the use of CIVO with molecular profiling technologies in both preclinical and Phase 0 trials in order to inform and de-risk oncology drug development.

On February 6, 2023 Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, reported that it now owns all rights to develop DF6002, its novel interleukin-12 (IL-12) cytokine investigational immunotherapy program, which is in Phase 1 clinical development, with dose escalation progressing successfully in monotherapy and in combination with nivolumab, in the U.S. and in Europe (Press release, Dragonfly Therapeutics, FEB 6, 2023, View Source [SID1234626893]). Clinical development is currently being carried out by Bristol Myers Squibb, but will be transferred to Dragonfly over the coming weeks.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very excited to have the Dragonfly developed IL12 asset back," said Joseph Eid, MD, Dragonfly’s President of Research and Development, who previously led the pioneering clinical development of KEYTRUDA. "Given the encouraging profile we have seen both in preclinical models and in the clinic to date, we are accelerating DF6002’s development across a range of indications and combinations."

"We have great respect for Bristol Myers Squibb, whose broad range of oncology agents and talented, experienced and committed team have made it a strong partner," said Bill Haney, Co-founder and CEO of Dragonfly Therapeutics.

Since an original 2017 collaboration focusing on hematology malignancies, BMS and Dragonfly have entered multiple additional collaborations which include both oncology and neuroinflammation targets. BMS has licensed six Dragonfly TriNKET drug candidates and has two of them presently in the clinic. BMS licensed a TriNKET from Dragonfly for neuroinflammation in January 2023.

"We appreciate the BMS team’s hard work on the development of DF6002, the most advanced drug in Dragonfly’s rich cytokine pipeline," said Bill Haney. "And we are excited that Dr. Eid, who has had such an extraordinary career rapidly and effectively advancing drugs in oncology, will now take charge of accelerating DF6002 in the clinic."

About DF6002
DF6002, Dragonfly’s extended half-life IL12 cytokine, is an investigational immunotherapy being evaluated alone and in combination with nivolumab in participants with locally advanced or metastatic solid tumors [NCT04423029]. DF6002 is a monovalent IL12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses. DF6002 has the potential to stimulate effective anti-tumor immunity in patients who are not eligible or not adequately responding to current therapies. DF6002 is the most advanced in a pipeline of cytokines that Dragonfly is developing to address the high unmet need in patients with advanced cancer.